Part B: Patients must have either measurable disease or must be evaluable for MIBG response without evidence of Response Evaluation Criteria in Solid Tumors (RECIST) measurable lesions; patients with neuroblastoma in bone marrow only are not eligible
Measurable or evaluable disease using Response Evaluation Criteria in Solid Tumors
Women with metastatic breast cancer, measurable or evaluable disease including bone metastasis only (as per the Response Evaluation Criteria in Solid Tumors [RECIST] v.)
Presence of measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST .).
Participants enrolled in the Phase I portion must have evaluable disease; participants enrolled in the Phase II portion must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) .
For Part : Participant must have evaluable disease. For Part : Participant must have measurable disease according to Response Criteria in Solid Tumors (RECIST) v.
Evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version ..
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) .
Evaluable disease, either measurable on physical examination or imaging by Response Evaluation Criteria in Solid Tumors (RECIST v., Appendix ), or by informative tumor marker(s).
Measurable or evaluable disease defined by Response Evaluation Criteria for Solid Tumors (RECIST) ver. .
For Parts A, B, C, D, E, and F: Have either measureable disease or nonmeasureable but evaluable bone disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST .)
Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
The patient must have disease that is measurable by standard imaging techniques, per the Response Evaluation Criteria in Solid Tumors, version . (RECIST .), or evaluable per RECIST .. (For patients with prior radiation therapy, measurable lesions must be outside of any prior radiation field[s], unless disease progression has been documented at that disease site subsequent to radiation.)
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . in dose escalation; measurable disease by RECIST . is required in dose expansion
Patients must have MBC that is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v. criteria. Patients with metastases limited to the bones are eligible.
Patients must have measurable disease, documented according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, or evaluable disease with a standard tumor marker (alpha-fetoprotein [AFP] and/or human chorionic gonadotropin [HCG]) greater than  times the upper limit of normal
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria.
The participant has the presence of measurable and/or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST Version .). Response Assessment in Neuro-Oncology (RANO) Criteria or Macdonald Criteria should be used for CNS tumors.
Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST). or pure lytic or mixed lytic-blastic bone lesions
Measurable and evaluable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) . criteria
Confirmed diagnosis of one of the following, and must be measurable or evaluable per RECIST . (solid tumors) or Lugano (NHL):
Have measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST .).
Patients must have evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) .
Have measurable or evaluable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) .
Metastatic disease that is evaluable radiologically by Response Evaluation Criteria in Solid Tumors (RECIST) or MD Anderson criteria, which will allow for bone-only disease
Measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST .).
Has measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v). for patients with solid malignancies and evaluable disease as assessed by bone scan and/or positron emission tomography (PET) scan
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria
Participants must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version . in the dose escalation portion of the trial. Participants in the expansion cohort must have measurable disease per RECIST version . or disease evaluable by assessment of tumor antigens.
Patients must have measurable/evaluable disease as per Response Evaluation Criteria in Solid Tumors version . (RECIST .) criteria
Measurable or evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) .
All patients must have evaluable disease as defined as:\r\n* Solid tumors must have a lesion evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version .\r\n* Central nervous system tumors will be evaluated by Response Assessment in Neuro-Oncology (RANO) criteria\r\n* Leukemia patients must have > % blasts (or blast equivalent) in the bone marrow
Measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) .
Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors version . (RECIST .); NOTE: Enrollment of patients with bone-only disease may be limited if we find we are not able to get adequate tissue for research correlates from bone biopsies
Have measurable or evaluable disease based on modified Response Evaluation Criteria in Solid Tumors (RECIST) for mesothelioma
Patient has measurable disease by RECIST version . (solid tumors) or Lugano (lymphoma) criteria or evaluable or measureable disease by Macdonald criteria (rHGG).
Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors Version (RECIST).
Evaluable or measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) v. criteria, and meet the requirements for the intended study cohort
Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) .; subjects with evaluable, but not measurable disease will be eligible for phase I
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v).
Measurable or evaluable disease; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria ., with radiologic scans within  days of day , cycle ; evaluable disease must include bone metastases (pleural effusions and ascites are not considered evaluable for this study)
Patients must have evaluable disease  defined as one of the following:\r\n* Response Evaluation Criteria in Solid Tumors (RECIST) . measurable disease OR\r\n* Evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST . definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related) AND a cancer antigen  (CA) that has doubled from the post-treatment nadir and is also greater than  times upper limit of normal (ULN)
Histological diagnosis of ameloblastoma; all stages are eligible; patients must have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) (version [v].)
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) .
Measurable or evaluable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST v.) criteria
Patients are not required to have measurable disease by traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria, as lesions in the pancreas are notoriously hard to measure radiographically; however, patients must have disease which is evaluable for resection
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable or non-measurable (but evaluable) disease as defined via Response Evaluation Criteria in Solid Tumors version . (RECIST .)
Evaluable disease for dose escalation, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) . for dose expansions
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors version . (RECIST v.)
Subjects with extracranial disease must have evaluable disease by Response Evaluation Criteria in Solid Tumors version . (RECIST v.); subjects affected by glioma must have evaluable disease by Response Assessment in Neuro-Oncology Criteria (RANO) criteria
Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria (not required for Part ); presence of evaluable OR measurable disease for Part 
CA- only disease without Response Evaluation Criteria in Solid Tumors (RECIST) . measurable or otherwise evaluable disease
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria or evaluable cancer via cancer antigen (CA) Gynecologic Cancer Intergroup (GCIG) criteria
Histologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesion; if applicable, Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
Measurable or evaluable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) . for non-GBM tumors and by Response Assessment in Neuro-Oncology (RANO) criteria for GBM
Evaluable disease, as follows:\r\n* For phase IA dose escalation: have the presence of any evaluable disease, including bone metastases, effusion, or cystic metastases\r\n* For phase IB extension only: have progressive and measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v .)
All patients must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
The disease is evaluable by imaging per Response Evaluation Criteria in Solid Tumors ..
Have measurable or non-measurable, evaluable disease by the revised response evaluation criteria in solid tumors (RECIST) v..
Measurable disease that is evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) v..
Have measurable disease or nonmeasurable but evaluable disease as defined by Response Evaluation Criteria in Solid Tumors, Version . (RECIST .).
Patients must have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . criteria
Participants must have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version .
Subjects who have evaluable lesion per guideline of Response Evaluation Criteria in Solid Tumors (RECIST) version ..
Disease evaluable for response by specific appropriate criteria.
Measurable or non-measurable disease (but radiologically evaluable) according to Response Evaluation Criteria in Solid Tumors (RECIST) v. criteria.
Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v .
Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version . or disease evaluable by assessment of tumor antigens including but not limited to cancer antigen (CA-) and prostate-specific antigen (PSA).
Measurable or evaluable disease will be included as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) .
Presence of measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST ., Eisenhauer et al. ).
The participant has metastatic disease or locally advanced disease that is measurable or nonmeasurable, but is evaluable disease by radiological imaging per Response Evaluation Criteria in Solid Tumors, Version . (RECIST .).
Evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.. criteria
Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) ..
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumors
Measurable or evaluable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version  (v )
Must have measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) . criteria
Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) . guidelines or evaluable disease; bone metastases must be evaluable
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) .
Measurable or non-measurable (but radiologically evaluable) disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria ..
At least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria In Solid Tumors Version .
Measurable disease by (Response Evaluation Criteria in Solid Tumors [RECIST .]) or evaluable disease
Measurable or non-measurable (but evaluable) disease as defined via Response Evaluation Criteria in Solid Tumors (RECIST) .
Measurable and/or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) . criteria and/or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria; bone only disease is allowed
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v) . mRECIST or elevated AFP
Subjects must have at least  measurable or evaluable tumor lesion according to RECIST . (Response Evaluation Criteria in Solid Tumors, version .)
Evaluable or measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST).
Measurable and/or evaluable disease as per the Response Evaluation Criteria In Solid Tumors (RECIST) version .) [Groups ,  of Part A and Group  of Part B] Inclusion Criteria Part A: MAD
Patients must have evaluable disease; measurable disease is not required; however, if measurable disease is present, it is defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) .; furthermore, if only evaluable disease is present, a relevant tumor marker (per investigator discretion) must be >=  times upper limit of normal (ULN) at baseline, and can be used as a response indicator
Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) .
Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable disease.
Measurable and/or evaluable disease based on Response Evaluation Criteria in Solid\n             Tumors (RECIST version .)
Has measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).
Metastatic or advanced breast cancer that is evaluable OR metastatic or advanced breast cancer that is measurable for response as per Response Evaluation Criteria in Solid Tumors (RECIST) .
Evaluable disease or disease measurable per modified Response Evaluation Criteria in Solid Tumors version . (RECIST v.)
Radiographically evaluable (measurable or non-measurable) disease (according to modified Response Evaluation Criteria In Solid Tumors (RECIST) . criteria
Presence of either evaluable disease or measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) .
Evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) v..
Patients with measurable or evaluable disease according to the response evaluation criteria in solid tumors
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria In Solid Tumors (RECIST) .
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) .
Histologically confirmed, measurable or evaluable disease; if disease is measurable Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
Phase Ib: Have evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) . criteria
Participants must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version . or disease evaluable by assessment of tumor antigens:
Have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) . and/or Prostate Cancer Working Group  (PCWG) criteria
Patients must have measurable or evaluable/non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) .; patients with bone only disease are not eligible; NOTE: for patients with metastatic disease in the liver, tumor burden should not be deemed significant (e.g., to no more than % of total liver volume as assessed by local review/investigator)
Subject must have evaluable, progressive, and measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, Version .
